{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:17:03Z","timestamp":1778699823870,"version":"3.51.4"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,8]],"date-time":"2014-10-08T00:00:00Z","timestamp":1412726400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0107582","type":"journal-article","created":{"date-parts":[[2014,10,8]],"date-time":"2014-10-08T17:53:09Z","timestamp":1412790789000},"page":"e107582","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Profibrinolytic Effect of the Epigenetic Modifier Valproic Acid in Man"],"prefix":"10.1371","volume":"9","author":[{"given":"Ott","family":"Saluveer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Ridderstr\u00e5le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00f3rd\u00eds J.","family":"Hrafnkelsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sverker","family":"Jern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,10,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1749-6632.1992.tb51622.x","article-title":"Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products","volume":"667","author":"JJ Emeis","year":"1992","journal-title":"Ann N Y Acad Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0038-1642716","article-title":"Gene targeting and gene transfer studies of the biological role of the plasminogen\/plasmin system","volume":"74","author":"P Carmeliet","year":"1995","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.thromres.2008.04.008","article-title":"Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin","volume":"122","author":"H Brogren","year":"2008","journal-title":"Thromb Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1160\/TH05-01-0033","article-title":"Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease","volume":"93","author":"C Dellas","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e26762","DOI":"10.1371\/journal.pone.0026762","article-title":"Platelets retain high levels of active plasminogen activator inhibitor 1","volume":"6","author":"H Brogren","year":"2011","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/01.CIR.103.15.1936","article-title":"Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis","volume":"103","author":"DE Newby","year":"2001","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1399-6576.2008.01741.x","article-title":"Impaired myocardial t-PA release in patients with coronary artery disease","volume":"52","author":"B Osterlund","year":"2008","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/ATVBAHA.107.143248","article-title":"Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease","volume":"27","author":"SD Robinson","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","article-title":"High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor","volume":"98","author":"AM Thogersen","year":"1998","journal-title":"Circulation"},{"key":"ref10","first-page":"673","article-title":"Contribution of PAI-1 in cardiovascular pathology","volume":"97","author":"MC Alessi","year":"2004","journal-title":"Arch Mal Coeur Vaiss"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(05)61044-6","article-title":"Impaired capacity for endogenous fibrinolysis in essential hypertension","volume":"352","author":"T Hrafnkelsdottir","year":"1998","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/01.HYP.0000137380.91476.fb","article-title":"Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension","volume":"44","author":"T Hrafnkelsdottir","year":"2004","journal-title":"Hypertension"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.amjhyper.2006.04.013","article-title":"Antihypertensive drugs and fibrinolytic function","volume":"19","author":"R Fogari","year":"2006","journal-title":"Am J Hypertens"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.HYP.0000210540.35296.62","article-title":"Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy","volume":"47","author":"W Ridderstrale","year":"2006","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11239-011-0595-4","article-title":"The impaired fibrinolytic capacity in hypertension is unaffected by acute blood pressure lowering","volume":"32","author":"W Ridderstrale","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1161\/CIRCULATIONAHA.113.003192","article-title":"Plasminogen Activator Inhibitor-1 Antagonist TM5441 Attenuates Nomega-Nitro-L-Arginine Methyl Ester-Induced Hypertension and Vascular Senescence","volume":"128","author":"AE Boe","year":"2013","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e31573","DOI":"10.1371\/journal.pone.0031573","article-title":"Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression","volume":"7","author":"P Larsson","year":"2012","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11239-012-0831-6","article-title":"Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells","volume":"35","author":"P Larsson","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvr028","article-title":"Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells","volume":"90","author":"S Dunoyer-Geindre","year":"2011","journal-title":"Cardiovasc Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"E Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/pds.2073","article-title":"Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study","volume":"20","author":"JB Olesen","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pds.2073","article-title":"Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study","volume":"20","author":"JB Olesen","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/00004872-199715120-00066","article-title":"High capacity for tissue-type plasminogen activator release from vascular endothelium in vivo","volume":"15","author":"U Wall","year":"1997","journal-title":"J Hypertens"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1055\/s-0037-1615762","article-title":"Extracellular nucleotides ATP and UTP induce a marked acute release of tissue-type plasminogen activator in vivo in man","volume":"85","author":"T Hrafnkelsdottir","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/STROKEAHA.111.622217","article-title":"Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases","volume":"43","author":"A Tjarnlund-Wolf","year":"2012","journal-title":"Stroke"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MBC.0b013e3282f3f9ec","article-title":"High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study","volume":"19","author":"S Koenig","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood.V76.5.930.930","article-title":"Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA\/PAI-1 complex in plasma","volume":"76","author":"WL Chandler","year":"1990","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/01.CIR.96.3.761","article-title":"Clearance of tissue plasminogen activator (TPA) and TPA\/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels","volume":"96","author":"WL Chandler","year":"1997","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1161\/01.CIR.91.2.284","article-title":"Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study","volume":"91","author":"V Salomaa","year":"1995","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01061993","article-title":"Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events","volume":"1","author":"PM Ridker","year":"1994","journal-title":"J Thromb Thrombolysis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","article-title":"Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction","volume":"2","author":"A Hamsten","year":"1987","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/01.ATV.20.8.2019","article-title":"Plasma levels of tissue plasminogen activator\/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study","volume":"20","author":"B Wiman","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/j.1538-7836.2004.00948.x","article-title":"Regulation of local availability of active tissue-type plasminogen activator in vivo in man","volume":"2","author":"T Hrafnkelsdottir","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/mol.65.3.520","article-title":"Valproic acid inhibits angiogenesis in vitro and in vivo","volume":"65","author":"M Michaelis","year":"2004","journal-title":"Mol Pharmacol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0107582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T15:35:48Z","timestamp":1598369748000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0107582"}},"subtitle":[],"editor":[{"given":"Hugo","family":"ten Cate","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,8]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0107582","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,8]]}}}